The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Shares in GSK (UK:GSK) (GSK), listed on the London Stock Exchange, increased 2% on Wednesday having gained 18% over the previous 12 months. GSK is currently being sued by nearly 75,000 plaintiffs ...

With the expiration of a contract to produce antibiotic medicines for Sandoz, GSK will shutter a 75-year-old manufacturing ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

The GSK share price is nearly 10% off its 52-week high, and this Fool is keen to take a closer look. Could it be a stock for ...

Pharmaceutical firm GlaxoSmithKline (GSK) has confirmed job losses at one of its UK sites. It is believed about 200 roles ...

GSK is closing down a facility and is winding down antibiotic manufacturing operations at another factory as Novartis’ Sandoz ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

GSK announced positive Phase II results for its mRNA seasonal influenza vaccine, showing strong immune responses against ...

GSK recently reported that its asthma drug Nucala (mepolizumab) met the primary endpoint in a Phase III trial treating ...

If I did not have it, I would certainly use this dip to buy the stock, given its extreme undervaluation and excellent growth prospects. The post With GSK’s share price down 9%, is it time for me to ...